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was carried out after IERB approval. Total of 120/157 patients 30 each, 56-58 yrs old,
with diagnosis of knee OA, Grade – II / III were randomized to receive total dose of
– placebo 800 mg, NRINF02 (Curcuma longa linn.-standardized extract) 500 mg and
GS 1500 mg and their combination orally, for 42 days with follow-up on 21st and
42nd day. Primary efficacy outcomes were measured using WOMAC, Visual Ana-
logue Scale [VAS], Clinician Global Impression of Change [CGIC] and clinical-exam-
ination and secondary efficacy outcome by recording number of paracetamol tab-
lets as rescue medication. Safety profile was monitored at each clinic visit by
recording adverse reactions. Chi-square test, repeated measures ANOVA and
mixedmodel analysis were performed using SPSS 16.0 and presented as inferential
statistics. RESULTS: Patients on NRINF02 showed significant decrease in -WOMAC
 p  0.05, VAS  p  0.05, CGIC  p  0.001, used lesser number of rescue
medications(p  0.05) and demonstrated greater clinical and subjective improve-
ment compared to placebo group. All study medications demonstrated acceptable
safety profile. CONCLUSIONS: Study patients exhibited acceptable tolerability and
efficacy profile with NRINF02 when assessed using algofunctional indices for OA.
NRINF02 may therefore be considered as an alternative treatment option in pa-
tients intolerant to NSAIDs presenting with uncomplicated knee OA.
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OBJECTIVES: To conduct a systematic review to estimate the disease burden of
Rheumatoid Arthritis in Mainland China. METHODS: Publications between 1990
and 2010 were systematically searched from 10 electronic databases. Observa-
tional studies consisting of disease burden of Rheumatoid Arthritis were included.
Data were extracted using a standardized form. Quality of searched publications
was evaluated by the quality rating scale. Meta –analysis of prevalence rates was
conducted using the generic inverse variancemodel.Meta-analysis of SF-36 quality
of life scores were performed to assess 8 dimensions by RevMan5.0 software, with
weightedmean difference (WMD) used as the indicator of intervention effect. Sen-
sitivity analyses were performed to evaluate the impact of different research
qualities. RESULTS: In total, 20 studies were included, which general quality was
evaluated asmoderate. The weighted prevalence was 0.42%(95%CIxF0.39%-0.45%).
The weighted prevalence in females was significantly higher than that in males.
But therewas no statistically significant difference on different periods, or between
the southern and northern sections of Mainland China. Themeta-analysis showed
that there was a statistically significant difference between WMD of the 8 dimen-
sions of the SF-36. Sensitivity analysis showed that the weighted results were
stable. The incidence rate of RA was 14.7/100 000. In some studies, it is estimated
that there was 4.92 healthy life year per patient lost in his life resulting from RA.
CONCLUSIONS: The prevalence of RA in Mainland China is similar to that of west-
ern countries. Considering the high disability risk of RA, additional economics
burden studies, especially indirect burden studies, will be helpful for enhance the
awareness of RA and to provide patients treatment options and support.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory
disease imposing a great burden on individuals and society, highlight by the intro-
duction of new expensive biologics within this decade. This study compared the
trend of health care expenditures and biologics costs due to rheumatoid arthritis
from 1999-2009.METHODS: This studywas based on data from theNational Health
Insurance Research Database (NHIRD) released by the National Health Research
Institute, which representing 99% of the entire population of Taiwan.We identified
all patients by both with a primary diagnosed code ICD-9-CM 714.0 and with RA
Catastrophic Illness certificate. Patients who fulfilled the American College of
Rheumatology criteria for the classification of RA are qualified to register in Cata-
strophic Illness file and can benefit for waiving the outpatient registration fee. The
indication for reimbursement the biologics were DAS28xa5.1 for two continuous
measures 1 month apart in Taiwan. RESULTS: After adjusting by using WHO 2000
population, we found the incidence rate of RA is stable around 0.01% from 1999 to
2009 in Taiwan. However the prevalence rate is increasing from0.07% to 1.13%. The
average annual growth rates of total medication cost for RA patients (51.6%) are
higher than the growth rates of total treatment cost for RA patient (36.7%) during
the study period from 1999 to 2009. In addition, Outpatient drug cost growth rates
(11.5%-44.1%) were much higher than that of inpatient drug growth rates (2.4%-
26.7%) during this period. Enbrel was reimbursed by the National Health Insurance
since 2003 and next year it reflected an 11.6% growth rate in expenditure. Although
there are three biologics reimbursed by NHI for qualified RA patients, Enbrel dom-
inates on the market. CONCLUSIONS: The introduction of biologics may benefit to
the decreasing rate of inpatient admission and costs.
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OBJECTIVES: To examine the mortality and medical cost during the first and sec-
ond year following fractures among elder women by different age groups.
METHODS: Using the inpatient and outpatient database of National Health Insur-
ance to define new hip fracture (ICD9 code 820, 733.14), vertebral fracture (ICD9
code 805, 806, 733.13), wrist fracture (ICD9 code 813, 733.12) and other fracture (ICD9
code 807, 808, 810, 811, 812, 821, 823, 733.10, 733.11, 733.15, 733.16, 733.19) cases
from 2006 to 2009. We divided age into ten groups between 50-100 years. The HR of
mortality and the incremental costs compared to the population without any frac-
ture history in each group were estimated by cox proportional survival model and
generalized linear model. RESULTS: The HR of mortality after hip fracture in each
group ranged from 19.67 to 1.43 while after vertebral fracture ranged from 5.60 to
1.11. The extra costs (in NTD) of hip fracture during first year in each group were
NT$178 535, NT$158 831, NT$184 334, NT$190 206, NT$179 261, NT$160 565, NT$136
195, NT$136 194, NT$110 476, NT$41 194. In the second year, the extra costs of hip
and clinical vertebral fracture were NT$221 036 and NT$135 912, respectively.
CONCLUSIONS: Hip and vertebral fractures result in significant mortality and
costs. These results indicate potential benefits from interventions aimed at reduc-
ing fracture incidences.
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OBJECTIVES: Rheumatoid arthritis (RA) is associated with poor quality of life and
higher health care cost. This study aimed to assess the hospitalization costs of
rheumatoid arthritis (RA) and to characterize predictors of these costs.METHODS:
A total of 676 RA patients were randomly selected by stratified two-stage sampling
from the China Basic Health Insurance database in 2009 and 2008. All information
of patient demographic characters, clinical and costs were collected for the analy-
sis. We used generalized estimating equations to examine potential predictors of
the costs. RESULTS: Among 676 RA patients (mean age 57.8 years; 75.2% female),
Themean hospital length-of-stay was 19.4 days for RA patients with basic medical
insurance for urban employees and 15.0 days for those patients with basic medical
insurance for urban residents. The average inpatient cost was Chinese Yuan (CNY)
8521.5 (median:xx6608.7, IQR:xx4223.5-xx10383.3), higher than those without
RA(CNY7670) and the average drug cost accounts for 49.95%of the total cost (mean:
xx5295.3). Themultiple linear regressions showed that the hospital cost of patients
with basic medical insurance for urban employees had 39.6% higher costs than
those with basic medical insurance for urban residents(P0.001). Patients from
tertiary hospitals had 97.8% higher costs than those from primary hospitals; (P 
0.001) and patients from municipalities had 46.0% higher costs than those from
county-level cities( P  0.01). CONCLUSIONS: Patients with RA is associated with
high hospitalization costs. Costs are now driven predominantly by the cost of
drugs, primarily biologic agents. and sociodemographic characteristics such as
types of health insurance and levels of hospitals also play an important role in
determination of costs.
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OBJECTIVES: Ankylosing spondylitis (AS) is associated with poor quality of life and
higher health care cost. This study aimed to assess the inpatient costs of AS and to
characterize predictors of these costs. METHODS: A total of 560 AS patients were
randomly selected by stratified two-stage sampling from the China Basic Health
Insurance database in 2009. All information of patient demographic characters,
clinical and costs were collected for the analysis. We used generalized estimating
equations to examine potential predictors of the costs. RESULTS: Among 560 AS
patients (mean age 55.7 years;57% female), Themeanhospital length-of-staywas
15.2 days for AS patients with basicmedical insurance for urban employees and 9.8
days for those with basic medical insurance for urban residents(P0.001). The
average inpatient cost was RMB 8173.3 yuan (median:4368.7, IQR:2836.1-7399.7)
and the average medical service cost accounts for 68.0% of the total cost (mean:
5560.5; median:2376.0, IQR:1395.0-3882.7). The multiple linear regressions showed
that the patients from tertiary hospitals had 84.7% higher costs than those from
primary hospitals (P  0.001) , patients from the east area have 30.7% higher costs
than those from the west area ( P  0.01), and patients from municipalities had
72.5% higher costs than those from county-level cities( P  0.05). CONCLUSIONS:
Patients with AS is associated with high hospital costs. Costs are now driven pre-
dominantly by the cost of medical service, and sociodemographic characteristics
such as regions and levels of hospitals also play an important role in determination
of costs.
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OBJECTIVES: To determine factors that are responsible for the cost differential
between private and public health facilities through the assessment of the cost per
day of managing six diseases in selected health facilities in Bayelsa State, Nigeria.
METHODS: Prescriptions generated in three tertiary / public hospitals and three
private hospitals for management of Malaria, Typhoid Fever, Essential Hyperten-
sion, Diarrhea, Pneumonia, and Rheumatoid Arthritis over a specified period were
evaluated to determine direct cost of drugs. Questionnaires were used to obtain
relevant data on staff wage bills, and utility bills. Data were analyzed to obtain the
cost per day for each diagnosis, number of days pay required to pay for the treat-
ment using the newly approved N18, 000.00 minimum wage by the Federal Gov-
ernment of Nigeria. RESULTS: Public facilities pay much higher wage bill; all facil-
ities rely heavily on alternative power source; public facilities utilized lesser
number of drugs and shorter duration; polypharmacy, co-morbidities, treatment
duration and number of drug prescribed determine cost of treatment; treatment
cost for all six disease conditions was generally higher in the private facilities;
Hypertension was the most costly to treat at a total cost of N20,570 for 30days
requiring 36.28 days pay to afford; malaria was cheapest to treat for N227 requiring
0.4 day pay; the cost of treatment of the selected diseases are high and
unaffordable. CONCLUSIONS: Generally, costs of prescribed drugs were expensive
in the private facilities. The costs of treatment were also generally not affordable
when viewed from the point of globally accepted affordability standard. Therefore
the need to make the cost of drugs cheaper for health care to be more affordable
becomes imperative.
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OBJECTIVES: Patients with rheumatoid arthritis in Taiwan might receive lifelong
reimbursement for biologics from the Bureau of National Health Insurance (BNHI)
if they satisfied required criteria, which might have a significant impact on the
annual budgets of the BNHI. The objective of this study was to analyze and com-
pare the cost-effectiveness among existing reimbursed eleven possible combina-
tions of biological treatment strategies, while under limited and lifelong treatment
duration assumptions. METHODS: Under limited and lifelong treatment duration
assumptions, Monte-Carlo simulation was used to compare the cost-effectiveness
of eleven possible combinations of biological treatment (Adalimumab, Etanercept,
and Rituximab) strategies in patients with active RA. Treatment duration assump-
tions, effectiveness and utility parameters for different biological treatment strat-
egies were obtained from published papers. Direct medical and drug costs were
estimated according to Taiwan’s National Health Insurance fee schedule for 2011
and the National Health Insurance payment standard. Probability sensitivity anal-
ysis was applied after Monte-Carlo simulation. Incremental costs per quality-ad-
justed life-year (QALY) between the strategies were calculated. Both cost and ef-
fectiveness were discounted at the rate of 3.5%. RESULTS: There were differences
between the results for limited and lifelong treatment duration assumptions. For
limited treatment duration, stratagies with Adalimumab as the first line biologic
(including Adalimumab only; Adalimumab followed by Rituximab; Adalimumab,
Rituximab and Etanercept; Adalimumab, Etanercept and Rituximab; Etanercept,
Adalimumab and Rituximab) were more cost-effective. For lifelong treatment du-
ration, however, strategies with Etanercept as the first line biologic (including Et-
anercept only; Etanercept followed by Rituximab; Etanercept, Rituximab and Ada-
limumab; Etanercept, Adalimumab and Rituximab) were more cost-effective.
CONCLUSIONS: From the Bureau of National Health Insurance point of view, there
seems to be a difference in defining the more cost-effective strategy under the
assumptions, however, the strategy using Etanercept as the first line biologic fol-
lowed by Adalimumab and Rituximab was cost-effective under both assumptions.
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OBJECTIVES: Rheumatoid arthritis (RA) critically impair the quality of life of pa-
tients. Biologic treatments represent a therapeutic alternative for patients who
failed non-biological disease-modifying antirheumatic drugs (DMARDs). Their high
cost, however, is a challenge for clinicians and decision makers. The aim of this
study was to assess the cost-effectiveness of biologic alternatives to treat RA cur-
rently available in China, from a societal perspective.METHODS: A decision anal-
ysis model was developed to simulate the clinical course of patients treated with
Infliximabmethotrexate (MTX), Etanercept, EtanerceptMTX, Adalimumab and
AdalimumabMTXas first-line therapies, aswell as associated costs over one-year
period. Patients were treated for 1-year without discontinuation or switch due to
the lack of efficacy or a major adverse event (AE). Effectiveness measures were
proportion of patients achieving 20%, 50%, 70% improvement following the Amer-
ican College of Rheumatology (ACR20, ACR50 and ACR70) criteria. Costs included
biologics, concomitant drugs, medical follow-up and side effects management.
Clinical response of alternatives and administration costs were extracted from
published literature, while drug costs were collected from National Development
and Reform Commission databases of China. RESULTS: When compared with
InfliximabMTX, Adalimumab and AdalimumabMTX, Etanercept is effective
over other biologic treatments except in ACR70 2% less effectiveness compared
with InfliximabMTX. Etanercept is 56,179US$ less than InfliximabMTX (the
most costly alternative) and 30% more patients meet the ACR20 criteria regarding
Adalimumab (the least effective alternative). When compared with
InfliximabMTX, Adalimumab and AdalimumabMTX, EtanerceptMTX is dom-
inant over other biologic in either ACR20, ACR50 andACR70.CONCLUSIONS:Due to
their lower costs and favorable effectiveness profile, Etanercept or
EtanerceptMTX are both less costly and the most effective over other biologic
treatments in the management of RA in China.
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OBJECTIVES: Denosumab has recently been adopted in the National Health Insur-
ance (NHI) program as a therapy in treating and preventing osteoporosis and the
reimbursed price for denosumab is NT$12,688. It is important to assess if deno-
sumab represents good value of money. The aim of this study was to evaluate the
potential cost-effectiveness of denosumab in the treatment of osteoporosis among
postmonopausal women in Taiwan. METHODS: A Markov cohort model was
adapted to estimate and costs per quality-adjusted life-year (QALY) gained of a
3-year denosumab treatment compared with no treatment and the current treat-
ments, alendronate, ibandronate, raloxifene or zoledronate used in Taiwan. The
model was populated with costs and epidemiological data for Taiwan and the
patients fitted the model were corresponding to the patients in the “Fracture Re-
duction Evaluation of Denosumab in Osteoporosis every 6 Months” (FREEDOM)
trial. One-way and probabilistic sensitivity analyses were conducted to assess pa-
rameter uncertainty. RESULTS: In the base-case analysis, denosumab was shown
to be “cost saving” compared to alendronate, ibandronate, as well as raloxifene.
The results remain robust regardless of whether GI event was presence or the
annual drug cost of denosumab was set higher. In the base-case when denosumab
was compared to zoledronate, the ICER was NT$1,248,366 per QALY gained.
CONCLUSIONS: Based upon currently available data, denosumab is considered
cost-saving compared with alendronate, ibandronate and raloxifene and was
found to be cost-effective when compared with zoledronate.
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OBJECTIVES: In November 2011, Center for Drug Evaluation completed the project
which aimed to re-evaluate the currently reimbursed biologics for rheumatoid
arthritis (RA), and to establish the evidence-based revision rules of reimbursed
items covered by National Health Insurance (NHI). As part of the project, this study
reviewed the cost-effectiveness of reimbursed biologics (etanercept, adalimumab
and rituximab) and other non-reimbursed biologics for adult patients.METHODS:
Electronic databases including PubMed, CEPS (Chinese Electronic Periodical Ser-
vices) and CETD (Chinese Electronic Theses and Dissertation Service) were
searched up to October 2011. A total of 130 articles were reviewed and 37 were
identified. The SIGN 50 instrument was subsequently applied to assess the quality
of evidence. To present the differences among studies, we summarized the cost-
effectiveness of biologics for DMARD-IR (inadequate response to disease-modify-
ing anti-rheumatic drugs) and TNF-IR patients (inadequate response to tumor ne-
crosis factor-alpha inhibitors), respectively. RESULTS: For DMARD-IR patients,
twenty cost-effectiveness analyses (CEAs), most of high quality, were included. In
summary, two reimbursed biologics including etanercept and adalimumab were
considered as cost-effective alternatives in most foreign insurers comparing with
DMARDs. Combination therapies of biologics andmethotrexatewere cost-effective
comparing with monotherapy of biologics. However, the findings were still incon-
sistent when comparing etanercept with adalimumab, For TNF-IR patients, 10
CEAs, most of high quality, were included. Overall, rituximab was considered cost-
effective in most foreign insurers. CONCLUSIONS: Existing studies suggested that
the reimbursed biologicswere cost-effective alternatives inmost foreign countries.
Nevertheless the cost-effectiveness of technologies might vary across countries,
because the health care setting, clinical pattern, characteristics of patients, and
relative prices are difference in nature. A localized decision analytic model is still
needed formore relevant and precise assessment. This review, however, limited by
the research resource, provided only the preliminary evidence to inform the deci-
sion making.
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OBJECTIVES: To assess co-morbidity, quality of life (QOL), work/productivity loss,
and medical resource utilization (MRU) in patients with Ankylosing Spondylitis
(AS) in urban China. METHODS: Patients’ self-reported data were collected from
2010 National Health and Wellness Survey (NHWS). This survey represents urban
population 18 years and older. QOLwasmeasured by the physical component score
(PCS) and mental component score (MCS) of the Short Form-12 (SF-12). Loss of
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